Durable response to afatinib in advanced lung adenocarcinoma harboring a novel NPTN-NRG1 fusion: a case report.
Afatinib
Lung cancer
NRG1 fusion
Next-generation sequencing (NGS)
Journal
World journal of surgical oncology
ISSN: 1477-7819
Titre abrégé: World J Surg Oncol
Pays: England
ID NLM: 101170544
Informations de publication
Date de publication:
16 Aug 2023
16 Aug 2023
Historique:
received:
09
05
2023
accepted:
29
07
2023
medline:
18
8
2023
pubmed:
17
8
2023
entrez:
16
8
2023
Statut:
epublish
Résumé
NRG1 fusions are rare oncogenic drivers in solid tumors, and the incidence of NRG1 fusions in non-small cell lung cancer (NSCLC) was 0.26%. It is essential to explore potential therapeutic strategies and efficacy predictors for NRG1 fusion-positive cancers. We report an advanced lung adenocarcinoma patient harboring a novel NPTN-NRG1 fusion identified by RNA-based next-generation sequencing (NGS), which was not detected by DNA-based NGS at initial diagnosis. Transcriptomics data of the tissue biopsy showed NRG1α isoform accounted for 30% of total NRG1 reads, and NRG1β isoform was undetectable. The patient received afatinib as fourth-line treatment and received a progression-free survival (PFS) of 14 months. This report supports afatinib can provide potential benefit for NRG1 fusion patients, and RNA-based NGS is an accurate and cost-effective strategy for fusion detection and isoform identification.
Sections du résumé
BACKGROUND
BACKGROUND
NRG1 fusions are rare oncogenic drivers in solid tumors, and the incidence of NRG1 fusions in non-small cell lung cancer (NSCLC) was 0.26%. It is essential to explore potential therapeutic strategies and efficacy predictors for NRG1 fusion-positive cancers.
CASE PRESENTATION
METHODS
We report an advanced lung adenocarcinoma patient harboring a novel NPTN-NRG1 fusion identified by RNA-based next-generation sequencing (NGS), which was not detected by DNA-based NGS at initial diagnosis. Transcriptomics data of the tissue biopsy showed NRG1α isoform accounted for 30% of total NRG1 reads, and NRG1β isoform was undetectable. The patient received afatinib as fourth-line treatment and received a progression-free survival (PFS) of 14 months.
CONCLUSIONS
CONCLUSIONS
This report supports afatinib can provide potential benefit for NRG1 fusion patients, and RNA-based NGS is an accurate and cost-effective strategy for fusion detection and isoform identification.
Identifiants
pubmed: 37587479
doi: 10.1186/s12957-023-03129-z
pii: 10.1186/s12957-023-03129-z
pmc: PMC10428614
doi:
Substances chimiques
Afatinib
41UD74L59M
RNA
63231-63-0
NRG1 protein, human
0
Neuregulin-1
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
246Subventions
Organisme : Chinese Academy of Medical Sciences(CAMS) Innovation Fund for Medical Sciences
ID : 2021-I2M-1-012
Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Jonna S, Feldman RA, Swensen J, et al. Detection of NRG1 gene fusions in solid tumors. Clin Cancer Res. 2019;25:4966–72.
doi: 10.1158/1078-0432.CCR-19-0160
pubmed: 30988082
pmcid: 7470623
Drilon A, Duruisseaux M, Han JY, et al. Clinicopathologic features and response to therapy of NRG1 fusion–driven lung cancers The eNRGy1 Global Multicenter Registry. J Clin Oncol. 2021;39:2791–802.
doi: 10.1200/JCO.20.03307
pubmed: 34077268
pmcid: 8407651
Fernandez-Cuesta L, Thomas RK. Molecular pathways: targeting NRG1 fusions in lung cancer. Clin Cancer Res. 2015;21:1989–94.
doi: 10.1158/1078-0432.CCR-14-0854
pubmed: 25501131
Rodriguez-Pinto D, Sparkowski J, Keough MP, et al. Identification of novel tumor antigens with patient-derived immune-selected antibodies. Cancer Immunol Immunother. 2009;58:221–34.
doi: 10.1007/s00262-008-0543-0
pubmed: 18568347
Pinkas-Kramarski R, Shelly M, Guarino BC, et al. ErbB tyrosine kinases and the two neuregulin families constitute a ligand-receptor network. Mol Cell Biol. 1998;18:6090–101.
doi: 10.1128/MCB.18.10.6090
pubmed: 9742126
pmcid: 109195
Forster JA, Paul AB, Harnden P, et al. Expression of NRG1 and its receptors in human bladder cancer. Br J Cancer. 2011;104(7):1135–43.
doi: 10.1038/bjc.2011.39
pubmed: 21364580
pmcid: 3068491
Raj EH, Skinner A, Mahji U, et al. Neuregulin 1-alpha expression in locally advanced breast cancer. Breast. 2001;10:41–5.
doi: 10.1054/brst.2000.0182
pubmed: 14965558
Fernandez-Cuesta L, Plenker D, Osada H, et al. CD74-NRG1 fusions in lung adenocarcinoma. Cancer Discov. 2014;4:415–22.
doi: 10.1158/2159-8290.CD-13-0633
pubmed: 24469108
Heining C, Horak P, Uhrig S, et al. NRG1 fusions in KRAS wild-type pancreatic cancer. Cancer Discov. 2018;8:1087–95.
doi: 10.1158/2159-8290.CD-18-0036
pubmed: 29802158